RESUMO
Available assays for circulating levels of activated protein C (APC) are either time-consuming or difficult to use in a routine laboratory, or have a detection limit above normal levels. We have developed a simplified assay that measures both the in vivo free APC and the in vivo APC complexed to PC inhibitor (PCI). We measured APC levels, with both assays, in 339 plasma samples, 165 from patients with venous thromboembolism (VTE) and 174 from healthy individuals. The mean APC level in the 339 samples was 0.038±0.010 nM, using a previous assay that measures only the in vivo APC level, and 0.041±0.010 nM with the present new assay. The coefficient of correlation between assays was r=0.954 (P<0.001). The mean APC level in VTE patients was 0.034±0.009 nM (previous assay) and 0.037±0.009 nM (new assay), significantly lower than those in controls (P<0.001). In both groups there was a significant correlation between the levels obtained by the two assays (P<0.001). These results show that both assays are equivalent, and confirm that the APC level is lower in VTE patients than in healthy individuals. Therefore, the new simplified assay, which measures the sum of circulating free APC and APC complexed to PCI, may be used to estimate the level of circulating APC, and will allow its use in routine laboratories.
Assuntos
Proteína C/análise , Proteína C/metabolismo , Tromboembolia Venosa/sangue , Humanos , MasculinoRESUMO
OBJECTIVE: The metabolic syndrome (MetS) may contribute to the pathogenesis of venous thromboembolism (VTE), but this association requires additional investigation. APPROACH AND RESULTS: We performed a patient-level meta-analysis of case-control and cohort studies that evaluated the role of MetS and risk of unprovoked VTE. For case-control studies, odds ratios and 95% confidence intervals were calculated using logistic regression analysis to estimate the influence of individual variables on the risk of VTE; χ(2) tests for trend were used to investigate the effect of increasing number of components of MetS on the risk of VTE and to explore the influence of abdominal obesity on this relationship. For cohort studies, hazard ratios and 95% confidence interval were calculated using multivariable Cox regression analysis. Six case-control studies were included (908 cases with unprovoked VTE and 1794 controls): in multivariate analysis, MetS was independently associated with VTE (odds ratio, 1.91; 95% confidence interval, 1.57-2.33), and both MetS and abdominal obesity were better predictors of unprovoked VTE than obesity defined by the body mass index. Two prospective cohort studies were included (26,531 subjects and 289 unprovoked VTE events): age, obesity, and abdominal obesity, but not MetS were associated with VTE. CONCLUSIONS: Case-control but not prospective cohort studies support an association between MetS and VTE. Abdominal adiposity is a strong risk factor for VTE.
Assuntos
Síndrome Metabólica/complicações , Tromboembolia Venosa/epidemiologia , Adulto , Idoso , Estudos de Casos e Controles , Estudos de Coortes , Feminino , Humanos , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Obesidade Abdominal/complicações , Fatores de RiscoRESUMO
OBJECTIVE: To investigate the association of the THBD c.1418C>T polymorphism, which encodes for the replacement of Ala455 by Val in thrombomodulin (TM), with venous thromboembolism (VTE), plasma soluble TM, and activated protein C levels. In addition, human umbilical vein endothelial cells (HUVEC) isolated from 100 umbilical cords were used to analyze the relation between this polymorphism and THBD mRNA and TM protein expression. APPROACH AND RESULTS: The THBD c.1418C>T polymorphism was genotyped in 1173 patients with VTE and 1262 control subjects. Levels of soluble TM and activated protein C were measured in 414 patients with VTE (not on oral anticoagulants) and 451 controls. HUVECs were genotyped for the polymorphism and analyzed for THBD mRNA and TM protein expression and for the ability to enhance protein C activation by thrombin. The 1418T allele frequency was lower in patients than in controls (P<0.001), and its presence was associated with a reduced VTE risk, reduced soluble TM levels, and increased circulating activated protein C levels (P<0.001). In cultured HUVEC, the 1418T allele did not influence THBD expression but was associated with increased TM in cell lysates, increased rate of protein C activation, and reduced soluble TM levels in conditioned medium. CONCLUSIONS: The THBD 1418T allele is associated with lower soluble TM, both in plasma and in HUVEC-conditioned medium, and with an increase in functional membrane-bound TM in HUVEC, which could explain the increased activated protein C levels and the reduced VTE risk observed in individuals carrying this allele.
Assuntos
Predisposição Genética para Doença/epidemiologia , Polimorfismo Genético , Proteína C/genética , Trombomodulina/genética , Tromboembolia Venosa/genética , Adulto , Alelos , Estudos de Casos e Controles , Células Cultivadas , Células Endoteliais , Feminino , Marcadores Genéticos , Genótipo , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Proteína C/metabolismo , RNA Mensageiro/análise , Valores de Referência , Medição de Risco , Solubilidade , Trombomodulina/metabolismo , Tromboembolia Venosa/epidemiologia , Trombose Venosa/epidemiologia , Trombose Venosa/genéticaRESUMO
Oral anticoagulants (OACs) reduce activated protein C (APC) plasma levels less than those of protein C (PC) in lupus erythematosus and cardiac patients. Carriers of the H1 haplotype of the endothelial PC receptor gene (PROCR) have higher APC levels than non-carriers. We aimed to confirm these results in a large group of patients treated with OACs because of venous thromboembolism (VTE) and to assess whether the effect is influenced by the PROCR H1 haplotype. We evaluated APC, PC, and factor (F)II levels in 502 VTE patients (158 with and 344 without OACs) and in 322 healthy individuals. Mean APC, PC and FII levels were significantly lower in OAC patients than in patients not taking OACs. During anticoagulant therapy, the FII/PC ratios were independent of the PC values, whereas APC/FII and APC/PC ratios significantly increased when FII and PC levels decreased. Of the 22 OAC patients carrying the H1H1genotype, 11 (50%) showed APC/PCag ≥2.0 and 10 (45%) APC/FIIag ratios ≥2.0, whereas for the 49 OAC patients non-carrying the H1 haplotype these figures were 6 (12%) and 4 (8%), respectively (p<0.001). Barium citrate adsorption of plasma from OAC patients showed that most of the circulating free and complexed APC, but only part of PCag, is fully carboxylated. In conclusion, during anticoagulant therapy VT patients have APC levels disproportionately higher than the corresponding PC levels, mainly due to the presence of the PROCR H1 haplotype. Furthermore, a sufficiently carboxylated PC Gla-domain seems to be essential for PC activation in vivo.
Assuntos
Anticoagulantes/administração & dosagem , Antígenos CD/metabolismo , Proteína C/metabolismo , Receptores de Superfície Celular/metabolismo , Tromboembolia Venosa/tratamento farmacológico , Tromboembolia Venosa/genética , Adulto , Anticoagulantes/efeitos adversos , Antígenos CD/genética , Análise Mutacional de DNA , Receptor de Proteína C Endotelial , Feminino , Seguimentos , Haplótipos , Humanos , Masculino , Pessoa de Meia-Idade , Mutação/genética , Protrombina/metabolismo , Receptores de Superfície Celular/genética , Tromboembolia Venosa/sangue , Adulto JovemRESUMO
INTRODUCTION: Behçet's disease is a vasculitis of unknown cause in which thrombosis occurs in about 25% of patients. Two haplotypes of the endothelial protein C receptor gene, H1 and H3, are associated with the risk of thrombosis. Thus, the objective of this study was to evaluate the influence of these haplotypes on the thrombosis risk in Behçet's disease. MATERIAL AND METHODS: We evaluated the H1 and H3 haplotypes in 87 patients with Behçet's disease, 19 with and 68 without a history of thrombosis, and in 260 healthy individuals. We also measured protein C, activated protein C, and soluble endothelial protein C receptor levels in all individuals. RESULTS: The presence of the H1 haplotype seemed to protect Behçet's patients against thrombosis (odds ratio 0.21; 95% CI 0.1-0.8; p=0.023), whereas the frequency of the H3 haplotype was lower in patients than in control individuals (0.19; 0.1-0.5; p=0.006). Furthermore, the H1 haplotype was associated with increased levels of activated protein C, whereas the H3 haplotype was associated with the highest soluble endothelial protein C levels. Moreover, activated protein C levels were lower in patients with than in patients without posterior uveitis (p<0.001). CONCLUSIONS: These findings indicate that the H1 haplotype protects Behçet's patients from thrombosis, likely via increased levels of activated protein C, whereas individuals carrying the H3 haplotype seem to be protected from the clinical manifestations associated with Behçet's disease, probably via increased soluble endothelial protein C levels.
Assuntos
Antígenos CD/genética , Síndrome de Behçet/epidemiologia , Síndrome de Behçet/genética , Predisposição Genética para Doença/genética , Haplótipos/genética , Receptores de Superfície Celular/genética , Trombose/epidemiologia , Trombose/genética , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Comorbidade , Receptor de Proteína C Endotelial , Feminino , Predisposição Genética para Doença/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Fatores de Risco , Espanha/epidemiologia , Adulto JovemRESUMO
The protein C anticoagulant pathway plays a crucial role as a regulator of the blood clotting cascade. Protein C is activated on the vascular endothelial cell membrane by the thrombin-thrombomodulin complex. The endothelial protein C receptor binds protein C and further enhances protein C activation. Once formed, activated protein C down-regulates thrombin formation by inactivating factors Va and VIIIa and exerts cytoprotective effects through endothelial protein C receptor binding. An adequate generation of activated protein C depends on the precise assembly, on the surface of the endothelial cells, of thrombin, thrombomodulin, protein C, and endothelial protein C receptor. Therefore, any change in the efficiency of this assembly may cause a reduction or increase in activated protein C generation and modulate the risk of thrombosis. This review highlights the role of the endothelial protein C receptor in disease and discusses the association of its mutations with the risk of thrombosis.
Assuntos
Fatores de Coagulação Sanguínea/genética , Fatores de Coagulação Sanguínea/metabolismo , Receptores de Superfície Celular/genética , Receptores de Superfície Celular/metabolismo , Trombose/etiologia , Fatores de Coagulação Sanguínea/química , Humanos , Mutação , Receptores de Superfície Celular/químicaRESUMO
INTRODUCTION: The association of metabolic syndrome with venous thromboembolism (VTE) remains uncertain. Moreover, the relevance of abdominal obesity as an independent or related risk factor for VTE in the metabolic syndrome cluster is controversial. We aimed to evaluate the impact of metabolic syndrome and its individual components on VTE risk. METHODS: We conducted a case-control study to investigate the presence of metaoblic syndrome in 150 healthy individuals (43 ± 13 years) and 146 patients with a first objectively confirmed episode of deep venous thrombosis or pulmonary embolism (44 ± 13 years) who underwent a thrombophilia work up. RESULTS: Metabolic syndrome was present in 19% of cases and 8% of controls (P = 0.008). In the unadjusted analysis, metabolic syndrome was statistically associated with higher VTE risk [odds ratio (OR) = 2.7, 95% confidence interval (CI) 1.3-5.6]. However, hypertriglyceridemia (OR = 2.0, 95% CI 1.1-3.5), high glucose levels (OR = 2.0, 95% CI 1.2-3.5), and abdominal obesity (OR = 5.7, 95% CI 3.4-9.6) were also significantly associated with higher VTE risk. Abdominal obesity was the factor that had the highest OR. Moreover, after multivariate analysis in which each independent factor was adjusted for the others, only abdominal obesity remained statistically associated with higher VTE risk, revealing its relevance. Further adjustment for the presence of thrombophilia did not change the estimation. CONCLUSION: We conclude that, in subjects with a mean age of 44 years, metabolic syndrome increases VTE risk, although abdominal obesity is the pivotal factor.
Assuntos
Síndrome Metabólica/complicações , Síndrome Metabólica/etiologia , Tromboembolia Venosa/complicações , Adulto , Índice de Massa Corporal , Pesos e Medidas Corporais , Estudos de Casos e Controles , Feminino , Humanos , Lipídeos/sangue , Masculino , Região do Mediterrâneo/epidemiologia , Síndrome Metabólica/sangue , Síndrome Metabólica/epidemiologia , Pessoa de Meia-Idade , População , Prevalência , Fatores de Risco , Tromboembolia Venosa/sangue , Tromboembolia Venosa/epidemiologiaRESUMO
The contribution of hemorheological alterations in the prothrombotic condition in patients with metabolic syndrome (MS) remains a question of debate. We aimed to determine the association between MS and hemorheological parameters by means of a case-control study in 61 MS patients and 89 controls without MS. We determined blood viscosity at 230 s(-1) (Brookfield DVIII viscosimeter); plasma viscosity (Fresenius capillary plasma viscosimeter); erythrocyte aggregation at stasis and 3 s(-1) (MA-1 erythrocyte aggregometer); erythrocyte deformability (Rheodyn SSD at shear stresses of 12, 30 and 60 Pascals) and fibrinogen, along with anthropometric, lipidic and inflammatory parameters. MS patients showed increased blood viscosity (p = 0.018), plasma viscosity (p < 0.001), fibrinogen (p < 0.001), erythrocyte aggregation (p < 0.001), and decreased erythrocyte deformability (p = 0.033). In the multivariate regression analysis, fibrinogen and triglycerides predicted plasma viscosity and erythrocyte aggregability, whereas erythrocyte deformability was associated with alterations in the hydrocarbonate metabolism. Blood viscosity related to abdominal obesity. The logistic regression analysis revealed that of all the MS components, only hypertriglyceridemia independently predicts plasma hyperviscosity (OR 3.75 CI 1.44-9.77 p = 0.007) and erythrocyte hyperaggregability (OR 2.41 CI 1.00-5.80 p = 0.050). Erythrocyte hyperaggregability (EA > 8.23) and hyperfibrinogenemia (fibrinogen > 358 mg/dL) were independent predictors of MS: OR 3.34, 95% CI 1.40-7.93, p = 0.006 and OR 2.42 95% CI 1.04-5.66, p = 0.041, respectively. We conclude that MS is associated with an altered hemorheological profile related to inflammatory, lipidic and glucose intolerance parameters which could favor the development of thrombo-embolic and athero-thrombotic events in MS patients.
Assuntos
Hemorreologia , Síndrome Metabólica/sangue , Adulto , Idoso , Contagem de Células Sanguíneas , Glicemia/análise , Índice de Massa Corporal , Proteína C-Reativa/análise , Estudos de Casos e Controles , Colesterol/sangue , Índices de Eritrócitos , Feminino , Fibrinogênio/análise , Hemoglobinas Glicadas/análise , Humanos , Insulina/sangue , Masculino , Pessoa de Meia-Idade , Triglicerídeos/sangue , Relação Cintura-QuadrilRESUMO
INTRODUCTION: The role that hyperhomocysteinemia (HH) and the C677T mutation in 5,10-methylenetetrahydrofolate reductase (MTHFR) play in splanchnic vein thrombosis (SVT) remains unclear due to this unusual thrombotic location. OBJECTIVE: To analyse the possible association of HH with the C677T mutation in the MTHFR gene in SVT. MATERIAL AND METHODS: We determined homocysteine levels and the C677T MTHFR mutation, along with classical cardiovascular risk factors, in 48 patients with SVT (18 Budd-Chiari syndrome, 11 mesenteric vein thrombosis, 19 portal vein thrombosis) and 84 controls. RESULTS: In the univariate analysis, patients with SVT showed statistically higher homocysteine levels (P =0.044). After adjusting for total cholesterol, differences disappeared (P =0.256). However, no differences in homocysteine levels were observed when comparing the three SVT types (P =0.199), even after adjusting for age and total cholesterol (P =0.095). In addition, the prevalence of the TT genotype was no different when controls were compared with patients with SVT (P =0.253) or with SVT subtypes (P =0.885). No association was found between HH (>15 µm) and the TT genotype in cases (P =0.404), controls (P =0.178), or in the different SVT subtypes (P =0.495). CONCLUSIONS: Our results suggest that HH and the homozygous genotype in the MTHFR C677T mutation do not seem to play a role in SVT development.
Assuntos
Hiper-Homocisteinemia/genética , Metilenotetra-Hidrofolato Redutase (NADPH2)/genética , Mutação , Circulação Esplâncnica , Trombose Venosa/genética , Adulto , Colesterol/metabolismo , Feminino , Genótipo , Homocisteína/genética , Humanos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , EspanhaRESUMO
There is little information regarding the behaviour of red blood cell deformability in macrocytosis. We have determined in 114 patients with macrocytosis (MCV > 97 fL) and in 115 age and sex-matched subjects with normocytosis (VCM < 97 fL) erythrocyte deformability by means of ektacytometric techniques (Rheodyn SSD) measuring the erythrocyte elongation index (EEI) at 12, 30 and 60 Pa. Patients with macrocytosis showed statistically higher EEI at all the shear stresses tested when compared with controls (p < 0.001). When patients with macrocytosis were classified according to their main diagnosis as hepatic or renal disease, HIV and miscellaneous, 66.7%, 41.7%, 36.7% and 33.3% of patients, respectively, showed a EEI 60 higher than 61.8% (mean value of the control group + 2 SD). Linear regression analysis demonstrates that MCV, bilirubin, triglycerides and alanine aminotransferase were the main variables influencing EEI 60. An increased surface/volume ratio of the red blood cells may be the main cause related with a higher erythrocyte deformability in a relevant percentage of macrocytosis. Further research is required to confirm our findings by designing case-control pathology-specific studies.